{"id":{"repo_id":"athens","oai_identifier":"oai:lib.uoa.gr:uoadl:1315147"},"canonical_url":"https://search.ndltd.org/etd/athens/oai:lib.uoa.gr:uoadl:1315147","repository":{"repo_id":"athens","name":"National and Kapodistrian University of Athens","base_url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh"},"display":{"title":"Targeted therapies for adult acute lymphoblastic leukemia","abstract":"Η θεραπεία της οξείας λεμφοβλαστικής λευχαιμίας με μονοκλωνικά αντισώματα είναι στοχευμένη/ εξειδικευμένη, με διαφορετικό μηχανισμό δράσης από την χημειοθεραπεία και διαφορετικές παρενέργειες. Ο συνδυασμός των στοχεμένων θεραπειων με την χημειοθεραπεία μειώνει τον κινδυνο υποτροπής της νόσου.","abstract_html":"Η θεραπεία της οξείας λεμφοβλαστικής λευχαιμίας με μονοκλωνικά αντισώματα είναι στοχευμένη/ εξειδικευμένη, με διαφορετικό μηχανισμό δράσης από την χημειοθεραπεία και διαφορετικές παρενέργειες. Ο συνδυασμός των στοχεμένων θεραπειων με την χημειοθεραπεία μειώνει τον κινδυνο υποτροπής της νόσου.","abstract_has_math":false,"creators":["Κουρτέση Χριστίνα"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014","date_published":"2014","updated_at":"2026-11-19T05:24:00Z","subjects":[],"languages":["English"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:1315147"],"render_values":[{"text":"uoadl:1315147","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/1315147","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/1315147","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Alib.uoa.gr%3Auoadl%3A1315147","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Κουρτέση Χριστίνα"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014"]},{"key":"dc:type","label":"Dc Type","values":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:1315147","https://pergamos.lib.uoa.gr/uoa/dl/object/1315147"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Η θεραπεία της οξείας λεμφοβλαστικής λευχαιμίας με μονοκλωνικά αντισώματα είναι στοχευμένη/ εξειδικευμένη, με διαφορετικό μηχανισμό δράσης από την χημειοθεραπεία και διαφορετικές παρενέργειες. Ο συνδυασμός των στοχεμένων θεραπειων με την χημειοθεραπεία μειώνει τον κινδυνο υποτροπής της νόσου.","The classification of acute lymphoblastic leukemia (ALL) is based on morphologic findings as well as immunophenotypic, cytogenetic and molecular abnormalities. Better understanding of the biology of these disorders has made possible better classification of patients into prognostic subsets with specific molecular targets for therapy. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies in children with ALL has resulted in similar complete response rates in adults. Prognosis has especially improved in mature– B-cell and T-lineage ALL. The role of MoAbs and molecular targeted therapies was evaluated in the current study. Antibody therapy is an alternative and attractive treatment approach in ALL since it is targeted, subtype specific and, compared to chemotherapy, has different mechanisms of action and side effects. The addition of monoclonal antibody therapy to chemotherapy appears to hold great promise in lessening relapse rates. Several new small molecules and chemotherapeutic agents will, it is hoped, also find a niche in the therapy for ALL. Early examples including DNA methyltransferase inhibitors, farnesyl transferase inhibitors, NOTCH1 inhibitors, mTOR inhibitors, proteasome inhibitors and heat shock protein antagonists will all hopefully find a role in the therapy for this challenging disorder."]},{"key":"dc:title","label":"Title","values":["Targeted therapies for adult acute lymphoblastic leukemia"]}]}],"canonical_facts":{"dc:creator":["Κουρτέση Χριστίνα"],"dc:date":["2014"],"dc:description":["Η θεραπεία της οξείας λεμφοβλαστικής λευχαιμίας με μονοκλωνικά αντισώματα είναι στοχευμένη/ εξειδικευμένη, με διαφορετικό μηχανισμό δράσης από την χημειοθεραπεία και διαφορετικές παρενέργειες. Ο συνδυασμός των στοχεμένων θεραπειων με την χημειοθεραπεία μειώνει τον κινδυνο υποτροπής της νόσου.","The classification of acute lymphoblastic leukemia (ALL) is based on morphologic findings as well as immunophenotypic, cytogenetic and molecular abnormalities. Better understanding of the biology of these disorders has made possible better classification of patients into prognostic subsets with specific molecular targets for therapy. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies in children with ALL has resulted in similar complete response rates in adults. Prognosis has especially improved in mature– B-cell and T-lineage ALL. The role of MoAbs and molecular targeted therapies was evaluated in the current study. Antibody therapy is an alternative and attractive treatment approach in ALL since it is targeted, subtype specific and, compared to chemotherapy, has different mechanisms of action and side effects. The addition of monoclonal antibody therapy to chemotherapy appears to hold great promise in lessening relapse rates. Several new small molecules and chemotherapeutic agents will, it is hoped, also find a niche in the therapy for ALL. Early examples including DNA methyltransferase inhibitors, farnesyl transferase inhibitors, NOTCH1 inhibitors, mTOR inhibitors, proteasome inhibitors and heat shock protein antagonists will all hopefully find a role in the therapy for this challenging disorder."],"dc:identifier":["uoadl:1315147","https://pergamos.lib.uoa.gr/uoa/dl/object/1315147"],"dc:language":["English"],"dc:title":["Targeted therapies for adult acute lymphoblastic leukemia"],"dc:type":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]},"updated_at":"2026-11-19T05:24:00Z"}